Chesapeake IRB Announces Acquisition of Institutional Biosafety Corporation
Columbia, MD (June 6, 2017) – Chesapeake IRB (“Chesapeake”), the leading technology-enabled independent institutional review board (“IRB”) serving the clinical research industry, announced it has acquired Institutional Biosafety Corporation (“IBC”), a provider of institutional biosafety committee services located in Rockville, MD.
The acquisition of IBC expands Chesapeake’s services with the capability to provide comprehensive review and oversight of research utilizing recombinant or synthetic DNA molecules, including clinical trials involving genetic engineering and gene therapy.
“We are excited to partner with IBC to offer comprehensive biosafety support services that will further serve our customers conducting biological and biomedical clinical research trials,” said Jeff Wendel, President and CEO of Chesapeake. “Together with our market leading IRB services, we now offer customers the ability to properly assess the biosafety precautions essential for mitigating risks to researchers and patients.”
“By utilizing the exceptional Chesapeake platform, the IRB reviews will be able to coordinate with IBC’s institutional biosafety committee services to offer the speed, efficiency, and quality needed for customers to grow their research capacity and safeguard research participants,” said Gil Price, founder and CEO of Institutional Biosafety Corporation.
Federal regulations require institutions to have institutional biosafety committee oversight if they are conducting research involving recombinant or synthetic nucleic acid molecules (r/sNA) and are funded by NIH or taking place at sites that receive NIH funding. Many privately-sponsored studies voluntarily implement institutional biosafety committee services due to their interest in seeking NIH funding, other third-party regulatory requirements, or for enhanced research safety oversight.
Chesapeake IRB is a portfolio company of Linden Capital Partners.
About Chesapeake IRB
Chesapeake IRB, an AAHRPP-accredited company, provides independent IRB submission and review services to pharmaceutical, biotech, and medical device companies, as well as academic medical centers and hospital systems. Its paperless, cloud-based submission and review platform, CIRBI, leads the field and has set the standard in review turnaround time, quality, and document accessibility. Headquartered in Columbia, MD, Chesapeake IRB has offices across the United States and a wholly owned subsidiary, IRB Services, with offices in Toronto and Montreal, Canada. Visit www.chesapeakeirb.com for more information.
About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life sciences industries. Linden’s strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden invests in middle market platforms in the medical products, specialty distribution, pharmaceutical, and services segments of healthcare. For more information, please visit www.lindenllc.com.